Twitter

Chordate Medical Holding AB (publ) Appoints Lago Kapital as Liquidity Provider for the Company’s Preferred Share

Chordate Medical Holding AB (publ) ("Chordate" or the "Company") has entered into a liquidity provider agreement for the Company's preferred share with Lago Kapital ("Lago").

Under the agreement, Lago will place bid and ask orders in Chordate's preferred share in accordance with and within the framework of Nasdaq Stockholm's regulations for liquidity provision. The purpose of the liquidity provider arrangement is to improve liquidity and reduce volatility. Lago's assignment will commence on March 17, 2025.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Chordate Medical Holding AB (publ) Appoints Lago Kapital as Liquidity Provider for the Company's Preferred Share

Chordate Medical Holding AB (publ) Appoints Lago Kapital as Liquidity Provider for the Company's Preferred Share

More press releases

Investor relations

Subscribe

Press releases and reports via E-mail.

Detta fält används för valideringsändamål och ska lämnas oförändrat.

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact

Anders Weilandt, CEO

+46(0)73-387 42 77 anders.weilandt@chordate.com

Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nasdaq First North Growth Market (ticker: CMH).

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter